Navigation Links
Soligenix to Present at 8th Annual BIO Investor Forum
Date:10/27/2009

PRINCETON, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Soligenix, Inc., (Soligenix or the Company) (OTC Bulletin Board: SNGX), formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that its Chief Financial Officer Evan Myrianthopoulos will present a company overview highlighting recent developments at the BIO Investor Forum.

The presentation will take place on Thursday, October 29, 2009 at 1:00 PM PDT at The Palace Hotel in San Francisco, CA.

The Soligenix presentation will be webcast live and archived for later replay. To access the webcast, please visit the company's investor page at http://www.soligenix.com/invest_sec.shtml. The replay will be available 24 hours after the live presentation and will be accessible for 30 days.

About the BIO Investor Forum

The 8th Annual BIO Investor Forum is an international conference featuring late-stage private and emerging public companies. This year's BIO Investor Forum will include healthcare venture and private equity investors, buy-side investors and research analysts, as well as business development executives from leading global pharmaceutical and mature biotechnology companies.

About Soligenix, Inc.

Soligenix, Inc. (Soligenix), formerly known as DOR BioPharma, Inc., is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation. orBec® is currently the subject of a confirmatory Phase 3 clinical trial for the treatment of acute GI GVH
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
2. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
3. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
4. Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDFs 20th World Diabetes Congress
5. Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009
6. Transdel Pharmaceuticals to Present at Two Investor Conferences
7. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 2009 BIOCOM INVESTOR CONFERENCE
8. Advanced Life Sciences to Present at 8th Annual BIO Investor Forum
9. Researchers Present a Novel, Automated, Efficient Environmental Disinfection Technology that Significantly Reduces C. difficile, VRE and MRSA Contamination
10. China Pharma Holdings, Inc. to Present at the Roth China Conference on October 14 at 12:00 pm ET
11. 17th International Process Development Conference to Feature Presentations on Safety, Process Development, Crystallization, PAT, Scale-Up and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... in spintronics, an electronic which is not only ... on their spin and the spin-related magnetism. Spin-charge ... signals and vice versa. Recently, the research group ... Physics at Johannes Gutenberg University Mainz in collaboration ... has for the first time realised a new, ...
(Date:8/28/2014)... 2014  Next month, executives from clinical trial marketing firm ... beginning with Patient-Centered Clinical Trials 2014 , to be ... , September 4-5. Patient recruitment experts Bonnie A. ... will share insights on the benefits of employing an ... – from media to mobile apps – can be used ...
(Date:8/28/2014)... PARK, Calif. , Aug. 28, 2014 /PRNewswire/ ... focused on developing novel mid- to late-stage cardiovascular ... $7.0 million in its first round of financing. ... Biomedical Investments and Hercules Bioventures with participation from ... entrepreneur and pharmaceutical executive, Dr. Larry Hsu ...
(Date:8/28/2014)... A new market research report ... available from Strategic Consulting, Inc., the leading information ... Market Review, Fourth Edition: Global Review of Microbiology ... and compares microbiology test volumes, market values and ... Asia, and forecasts future volumes and market values ...
Breaking Biology Technology:A new, tunable device for spintronics 2A new, tunable device for spintronics 3BBK Worldwide Leads Sessions at Key September Events 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3
... April 14 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), ... (MS), today announced that the independent Data Safety Monitoring ... MAESTRO-03 trial of dirucotide in patients with secondary progressive ... the trial continue as per the protocol. , This ...
... Calif., April 14 Zenobia Therapeutics, Inc., the ... the central nervous system, announced successful completion of ... Syntonix Pharmaceuticals, a wholly-owned subsidiary of Biogen Idec ... the agreement, Syntonix gains access to Zenobia,s technology ...
... Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) provides ... 2009 third quarter and nine-month period ended February 28, ... fiscal year 2009 now ending on February, 28. , ... February 28, 2009 in the range of $3,400,000 to ...
Cached Biology Technology:BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals 2Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 2Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 3Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 4Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 5
(Date:8/29/2014)... fold them: modern materials that are light, flexible and ... skin or electronic paper. , Making such concepts affordable ... new way of working with copper nanowires and a ... Previous success in the field of ultra-lightweight "aerogel monoliths" ... and silver nanowires. , By turning instead to ...
(Date:8/28/2014)... called TX Invasives is now available from the Lady ... at Austin for identifying harmful non-native plant, insect and ... the United States cause about $137 billion in economic ... clog waterways, kill native plants and more. , "By ... reporting where invasive species occur, we,re more likely to ...
(Date:8/28/2014)... University researchers have identified a handful of bacterial culprits ... Crohn,s disease and ulcerative colitis, using patients, own intestinal ... published Aug. 28 in the journal Cell . ... microbiota, which plays a critical role in the development ... a small number of bacterial species affect a person,s ...
Breaking Biology News(10 mins):Copper shines as flexible conductor 2Mobile app makes ID of harmful plants, insects in Texas a snap 2Yale study identifies possible bacterial drivers of IBD 2
... blanket to stave off the shivers? A new study ... in patients who have been cooled to prevent brain ... fevers are often cooled to reduce their core body ... cooling induces a natural and familiar response - shivering. ...
... COLUMBUS, Ohio A study comparing how two common ... oils, by themselves, can lower body fat in obese ... oils compared were safflower oil, a common cooking oil, ... in some meat and dairy products that has been ...
... unexpected role of iron in regulating biological production ... important implications for our understanding of ocean-climate interactions. ... production in the sunlit surface waters of the ... sequester large amounts of atmospheric carbon dioxide. ...
Cached Biology News:Two dietary oils, two sets of benefits for older women with diabetes 2Two dietary oils, two sets of benefits for older women with diabetes 3Two dietary oils, two sets of benefits for older women with diabetes 4Iron and biological production in the high-latitude North Atlantic 2Iron and biological production in the high-latitude North Atlantic 3
... Fingerprinting II Informatix ... an optional module ... component analysis, multidimensional ... and MANOVA, and ...
Fingerprinting II Informatix optional matrix types module, is an optional module that adds external similarity and distance matrix functions to the Fingerprinting II Informatix software package....
... is a completely redesigned and updated version ... accepts the full line of well-proven Alpha ... in thermal performance as the DNA Engine ... easy transport of protocols among platforms. ...
... Ideal for hand-held applications or for ... II with a hand-held eight-port disposable manifold ... than a multi-channel pipette. The StatMatic II ... bottle sizes and can completely fill a ...
Biology Products: